Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
Adipose-derived stem cell therapy is an approach in regenerative medicine that uses a patient’s own cells. The process involves collecting a small amount of fat tissue, isolating and expanding the stem cells in a specialized facility, and then administering them back into the body. While this treatment holds potential, it is natural for patients to have questions about the safety of the cell culturing process. Concerns about potential contamination or changes in the cells are valid and important. This article addresses these key concerns by explaining the stringent measures taken in Japan to ensure the quality and safety of stem cell cultures.
Key Safety Concerns in Cell Culturing
When considering a treatment that involves culturing your own cells, several safety questions may arise. These are not just technical details; they are fundamental to the integrity of the therapy. Common concerns include:
- Microbial Contamination: Could bacteria, fungi, or viruses contaminate the cells during the culturing process?
- Cellular Abnormalities: Is there a risk that the cells could undergo undesirable changes, such as genetic mutations, while being grown in the lab?
- Cross-Contamination: How can one be sure that the cells being returned are their own and have not been mixed with cells from another person?
- Quality and Potency: How is the quality and therapeutic potential of the expanded cells maintained and verified before administration?
Addressing these questions is a top priority for medical institutions and regulatory bodies involved in regenerative medicine in Japan.
Japan’s Regulatory Framework for Regenerative Medicine
Japan has a dedicated legal framework to oversee the safety of advanced medical treatments like stem cell therapy. The “Act on the Safety of Regenerative Medicine” requires that all medical institutions providing such therapies submit a detailed treatment plan to the Ministry of Health, Labour and Welfare for review. This plan must outline every aspect of the treatment, from cell collection to administration, including the procedures used for cell processing.
A critical component of this framework is the regulation of Cell Processing Facilities (CPFs). These are specialized laboratories where the stem cells are cultured. A CPF must obtain a license from the government, which is only granted if the facility meets strict standards for its structure, equipment, personnel, and quality management systems. This ensures that all cell processing is conducted in a highly controlled and safe environment.
Core Quality Control Measures in a Cell Processing Facility
Licensed CPFs in Japan implement a multi-layered approach to quality control to minimize risks like contamination and cellular abnormalities. These measures are meticulously documented and executed by trained professionals.
Aseptic Processing in a Controlled Environment
All cell handling is performed within a highly controlled cleanroom environment. These rooms use high-efficiency particulate air (HEPA) filters to maintain a sterile atmosphere, and air pressure is carefully managed to prevent outside contaminants from entering. Personnel must follow strict gowning procedures and use sterilized equipment and materials to perform all tasks, a practice known as aseptic technique.
Rigorous and Repeated Quality Testing
The cells undergo a series of rigorous tests at multiple stages of the culturing process. These tests are designed to confirm safety and quality:
- Sterility Tests: Samples are tested to ensure they are free from bacteria and fungi.
- Mycoplasma Tests: Specific tests are conducted to detect mycoplasma, a type of bacteria that can be difficult to identify and can affect cell function.
- Endotoxin Tests: This test checks for the presence of endotoxins, which are toxic substances released by certain bacteria.
- Cell Characterization and Viability: The cells are examined to confirm they retain the specific characteristics of mesenchymal stem cells and that a high percentage of them are alive and healthy. Karyotyping or other genetic analyses may also be performed to check for chromosomal abnormalities.
Strict Traceability and Management Systems
From the moment the fat tissue is collected to the final administration of the cultured cells, every sample is meticulously labeled and tracked. This robust traceability system prevents mix-ups and ensures that patients receive only their own (autologous) cells. All procedures, materials used, and test results are thoroughly documented, creating a complete history for each batch of cells.
What to Confirm Before Considering Treatment
While the processing of cells is highly regulated, the decision to undergo adipose stem cell therapy requires careful consideration and a thorough consultation with a physician. It is important to understand that this therapy may not be suitable for everyone, and its applicability depends on an individual’s health condition and medical history.
This treatment is provided as a non-insured, private medical service (Jiyushinryo). Before proceeding, you should have a detailed discussion with your doctor about the expected outcomes, potential risks and side effects, the estimated number of treatments, the total duration, and the associated costs. A physician’s assessment is essential to determine if you are an appropriate candidate for this therapy.
Adipose Stem Cell Therapy at Our Clinic in Osaka
At Grand Green Osaka Umekita Clinic, we provide adipose-derived stem cell therapy in compliance with Japan’s Act on the Safety of Regenerative Medicine. We partner with a licensed domestic cell processing facility that adheres to the strict quality control standards discussed here, ensuring that the cells are processed with the utmost care.
We believe that patient education is a crucial part of the treatment journey. Our team is dedicated to providing clear and comprehensive information to help you make an informed decision. If you would like to learn more about the specifics of our adipose stem cell therapy, including the process, fees, and potential risks, we encourage you to review our detailed information page or schedule a consultation at our clinic in Osaka. Our staff can also provide support in multiple languages.
For more details, please see our Adipose-Derived Stem Cell Therapy page: https://umekitaclinic.org/cell-therapy/stem-cell/en/
Summary: A Commitment to Safety in Advanced Medicine
The safety of adipose stem cell therapy in Japan is underpinned by a robust legal framework and the diligent implementation of strict quality control protocols at every step of the cell culturing process. The risks of contamination and cellular abnormalities are actively managed through advanced facility design, rigorous testing, and meticulous documentation. By understanding these safety measures, patients can approach regenerative medicine with greater confidence. The final step is always a personal consultation with a qualified physician to determine the most appropriate path for your individual health goals.
- Government OversightCompliant with national regulations
- Aseptic ProcessingIn a licensed, sterile facility
- Rigorous Quality TestingMultiple checks for safety & quality
- Strict TraceabilityEnsuring you receive your own cells
This diagram is a conceptual summary of the information in this article
References
- PubMed: Mesenchymal Stem Cell Secretome: Toward Cell-Free Therapeutic Strategies in Regenerative Medicine. (2017)
- PubMed: Clinical Efficacy and Safety of the Intra-articular Injection of Autologous Adipose-Derived Mesenchymal Stem Cells for Knee Osteoarthritis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial. (2023)
- PubMed: Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II Trial. (2019)
- PubMed: Intrathecal delivery of adipose-derived mesenchymal stem cells in traumatic spinal cord injury: Phase I trial. (2024)
- PubMed: ADSC-enriched adipose extract alleviates cartilage fibrosis in temporomandibular joint osteoarthritis by inhibiting chondrocyte senescence. (2025)
- PMC: Towards an advanced therapy medicinal product based on mesenchymal stromal cells isolated from the umbilical cord tissue: quality and safety data. (2014)
- PMC: Manufacturing and banking canine adipose-derived mesenchymal stem cells for veterinary clinical application. (2021)
- PMC: Volatile organic compounds (VOCs) to monitor cell expansion and microbial contamination of mesenchymal stromal cells (MSCs): a preliminary study. (2025)
- MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.